Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Industry News
Share your love
FDA Unveils Updated Guidance for Ophthalmic Drugs
The FDA has released a significant update for the pharmaceutical industry, unveiling a revised draft guidance titled “Quality Considerations for Topical Ophthalmic Drug Products.” This comprehensive guidance addresses crucial quality considerations for various ophthalmic drug products, including gels, ointments, creams,…
Top 10 Medical Devices in Ophthalmology
Medical technology has advanced significantly in recent years, providing numerous benefits to patients and healthcare professionals. In the field of ophthalmology, innovative medical devices have been developed that have revolutionized the way eye conditions are diagnosed and treated. Here are…
Azura Ophthalmics: Phase 2 Results for AZR-MD-001
Azura Ophthalmics reported positive top-line efficacy and safety outcomes from a phase 2 investigation of AZR-MD-001 in individuals experiencing Contact Lens Discomfort (CLD) due to challenges in comfortably wearing lenses and demonstrating signs of meibomian gland dysfunction (MGD). The trial…
The Evolution of Intraocular Lenses
Cataract is the most prevalent ophthalmic disease. Treatment of cataracts has been practiced for centuries using various surgical and nonsurgical procedures. However, avoidance of complications and attainment of high-quality postoperative visual rehabilitation were difficult in the years before the introduction…
How to Deal with the Epithelial Herpetic Keratitis
Trifluridine eye drop, acyclovir (ACV) ointment, ganciclovir gel, and oral ACV are still the main therapeutic agents. Cryopreserved amniotic membrane has been recently used as an adjuvant treatment. Resistance to ACV has become a concerning issue. The animal models of…
Retinal Vasculitis: Causes, Symptoms and Management
Retinal vasculitis is an inflammatory condition affecting the blood vessels of the retina. This inflammation can disrupt the normal blood flow, leading to complications that may compromise visual function. Pathophysiology In retinal vasculitis, inflammatory cells such as neutrophils, macrophages, and…
VSY Unveils Enova Advanced EDoF IOL at EPOMEC 2023
VSY Biotechnology, a leading company in ophthalmic innovations, made a notable presence at the 10th Evolving Practice of Ophthalmology Middle East Conference (EPOMEC 2023) in Dubai. The conference, held from 23-25 November, marked a significant moment for VSY Biotechnology as…
FDA Warns Amazon Over Sale of 7 Unapproved Eye Drops
The US Food and Drug Administration’s (FDA) Center for Drug Evaluation and Research (CDER) has issued a warning letter to e-commerce giant Amazon.com regarding the introduction of unapproved ophthalmic drug products into interstate commerce. The FDA’s warning, delivered in a…
CHMP Backs Bayer’s High-Dose Eylea for Retinal Diseases
Bayer announced on Friday that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of a high-dose formulation of the renowned eye drug Eylea for the treatment of wet age-related macular degeneration and…
VSY Biotechnology to Introduce a Novel Anti-VEGF for AMD
VSY Biotechnology GmbH is proud to announce the groundbreaking development of Varliciment, a revolutionary anti-VEGF agent for the treatment of age-related macular degeneration (AMD). Varliciment distinguishes itself from existing anti-VEGF agents like brolucizumab, namely Novartis’ Beovu, by being non-generic. This…